Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

Similar articles for PubMed (Select 23951165)

1.

EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1.

Sáinz-Jaspeado M, Huertas-Martinez J, Lagares-Tena L, Martin Liberal J, Mateo-Lozano S, de Alava E, de Torres C, Mora J, Del Muro XG, Tirado OM.

PLoS One. 2013 Aug 12;8(8):e71449. doi: 10.1371/journal.pone.0071449. eCollection 2013.

2.

Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize.

Sáinz-Jaspeado M, Lagares-Tena L, Lasheras J, Navid F, Rodriguez-Galindo C, Mateo-Lozano S, Notario V, Sanjuan X, Garcia Del Muro X, Fabra A, Tirado OM.

Mol Cancer Res. 2010 Nov;8(11):1489-500. doi: 10.1158/1541-7786.MCR-10-0060.

3.

Auto-stimulatory action of secreted caveolin-1 on the proliferation of Ewing's sarcoma cells.

Sengupta A, Mateo-Lozano S, Tirado OM, Notario V.

Int J Oncol. 2011 May;38(5):1259-65. doi: 10.3892/ijo.2011.963. Epub 2011 Mar 3.

4.

Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase.

Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J.

J Biol Chem. 2008 Jun 6;283(23):16017-26. doi: 10.1074/jbc.M709934200. Epub 2008 Apr 3.

5.

FOXM1 is an oncogenic mediator in Ewing Sarcoma.

Christensen L, Joo J, Lee S, Wai D, Triche TJ, May WA.

PLoS One. 2013;8(1):e54556. doi: 10.1371/journal.pone.0054556. Epub 2013 Jan 24.

6.

WT1 regulates angiogenesis in Ewing Sarcoma.

Katuri V, Gerber S, Qiu X, McCarty G, Goldstein SD, Hammers H, Montgomery E, Chen AR, Loeb DM.

Oncotarget. 2014 May 15;5(9):2436-49.

7.

The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.

Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB.

Oncogene. 2000 Dec 7;19(52):6043-52.

8.

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.

Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J.

Mol Cancer Res. 2002 Nov;1(1):2-11.

9.

ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways.

Ikeda AK, Judelson DR, Federman N, Glaser KB, Landaw EM, Denny CT, Sakamoto KM.

Mol Cancer Ther. 2010 Mar;9(3):653-60. doi: 10.1158/1535-7163.MCT-09-0812. Epub 2010 Mar 2.

10.

A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Sankar S, Tanner JM, Bell R, Chaturvedi A, Randall RL, Beckerle MC, Lessnick SL.

Mol Cell Biol. 2013 Nov;33(22):4448-60. doi: 10.1128/MCB.00241-13. Epub 2013 Sep 16.

11.

Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.

Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J.

FASEB J. 2005 Nov;19(13):1884-6. Epub 2005 Sep 15.

12.

Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors.

Cheng N, Brantley D, Fang WB, Liu H, Fanslow W, Cerretti DP, Bussell KN, Reith A, Jackson D, Chen J.

Neoplasia. 2003 Sep-Oct;5(5):445-56.

13.

Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gúrpide J, Otero-Motta AP, Caballero G, Amaral AT, Wai DH, Braun Y, Eisenacher M, Schaefer KL, Poremba C, de Alava E.

Br J Cancer. 2009 Jul 7;101(1):80-90. doi: 10.1038/sj.bjc.6605104. Epub 2009 Jun 2.

14.

Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.

Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J.

Oncogene. 2002 Oct 10;21(46):7011-26.

15.

Expression of therapeutic targets in Ewing sarcoma family tumors.

Ahmed AA, Sherman AK, Pawel BR.

Hum Pathol. 2012 Jul;43(7):1077-83. doi: 10.1016/j.humpath.2011.09.001. Epub 2011 Dec 21.

PMID:
22196127
16.

A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.

McKinsey EL, Parrish JK, Irwin AE, Niemeyer BF, Kern HB, Birks DK, Jedlicka P.

Oncogene. 2011 Dec 8;30(49):4910-20. doi: 10.1038/onc.2011.197. Epub 2011 Jun 6.

PMID:
21643012
17.

Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.

Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H, Notario V.

Cancer Res. 2006 Oct 15;66(20):9937-47.

18.

EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.

Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J.

J Cell Sci. 2004 Apr 15;117(Pt 10):2037-49. Epub 2004 Mar 30.

19.

E-cadherin cell-cell adhesion in ewing tumor cells mediates suppression of anoikis through activation of the ErbB4 tyrosine kinase.

Kang HG, Jenabi JM, Zhang J, Keshelava N, Shimada H, May WA, Ng T, Reynolds CP, Triche TJ, Sorensen PH.

Cancer Res. 2007 Apr 1;67(7):3094-105.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk